Class III β-tubulin expression and in vitro resistance to microtubule targeting agents

Abstract excerpt

BACKGROUND: Class III beta-tubulin overexpression is a marker of resistance to microtubule disruptors in vitro, in vivo and in the clinic for many cancers, including breast cancer. The aims of this study were to develop a new model of class III beta-tubulin expression, avoiding the toxicity associated with chronic overexpression of class III beta-tubulin, and study the efficacy of a panel of clinical and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Treatment and Pharmacology
• Share to Microtubule and mitosis dynamics
• Share to Synthesis and biological activity